Skip to content
Evigrade
CriticalClass Ic antiarrhythmic×Selective serotonin reuptake inhibitor (SSRI)

Updated · Methodology

Mechanism

Paroxetine strongly inhibits the enzyme CYP2D6 (paroxetine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). CYP2D6 clears a large part of flecainide, so paroxetine raises flecainide blood levels (flecainide SmPC, AEMPS). The documents give no figures for this pair, but flecainide has a narrow therapeutic range, and interactions that raise its levels can be life-threatening (flecainide SmPC, AEMPS). Flecainide prolongs the QT interval and widens the QRS complex by 12–20% (flecainide SmPC, AEMPS). According to the US label, QT lengthens by about 8% on average, mostly because of QRS widening (flecainide label, US Food and Drug Administration, FDA). According to the paroxetine FDA label, higher levels of CYP2D6 substrates that prolong the corrected QT interval (QTc) may lengthen QTc further and lead to torsade de pointes, other serious arrhythmias and sudden death (paroxetine FDA label).

Symptoms

Excess flecainide mainly affects the heart. The electrocardiogram (ECG) shows QRS widening and longer PR and QT intervals, and atrioventricular block, bradycardia and ventricular tachycardia appear. Low blood pressure, fainting, seizures, heart failure and cardiac arrest can follow (flecainide label, US Food and Drug Administration, FDA). Flecainide very commonly causes dizziness and visual disturbances such as double and blurred vision. Breathlessness and new or worsened arrhythmias are common (flecainide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). QT prolongation itself causes no symptoms, while torsade de pointes, seen rarely with flecainide, causes palpitations, dizziness and fainting (flecainide FDA label).

Management

The combination is contraindicated. In its September 2026 version, the US Food and Drug Administration (FDA) paroxetine label contraindicates paroxetine with drugs that prolong the QT interval and are CYP2D6 substrates, and flecainide meets both conditions according to its own labels (paroxetine FDA label; flecainide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and flecainide FDA label). The Spanish SmPCs are softer: use paroxetine with caution together with antiarrhythmics and other drugs that prolong QT, especially with bradycardia, heart disease, low potassium or low magnesium (paroxetine SmPC, AEMPS). If the patient still takes both, lower the flecainide dose if needed (paroxetine FDA label). Periodic trough flecainide levels may help (flecainide FDA label). Trough levels are usually 0.2–1.0 µg/mL, and adverse effects, especially cardiac ones, become more frequent above 0.7–1.0 µg/mL (flecainide SmPC, AEMPS). Before starting flecainide, correct low or high potassium and other electrolyte disturbances, severe bradycardia and marked hypotension (flecainide SmPC, AEMPS). If the PR interval reaches 0.3 seconds or QRS reaches 0.18 seconds, consider lowering the flecainide dose (flecainide FDA label). Stop flecainide in second- or third-degree atrioventricular block or right bundle branch block with left hemiblock unless a pacemaker is in place (flecainide FDA label). There is no specific antidote for flecainide excess, dialysis does not help, and treatment is supportive (flecainide SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Flecainide

Other interactions with Paroxetine